Not exact matches
TLC's first project, which is also a pilot project of the TRND program, focuses on repurposing an existing
small molecule drug, auranofin, initially
approved to treat rheumatoid arthritis in the mid-1980s.
In 1994, Schreiber and co-workers discovered that the proteins FKBP12 and mTOR are the simultaneous targets of the
small molecule rapamycin, now
approved for use as an immunosuppressant
drug given to patients after organ transplantations to help prevent rejection.
It also raises the possibility to interfere with these systems by any means (
small molecules, FDA
approved marketed
drugs) and evaluate the consequences on both neurogenesis and neuroplasticity.